Abstract: Slide Presentations |


Yasuo Sekine, MD*; Yukio Saitoh, MD; Hidemi Suzuki, MD; Hironobu Wada, MD; Shigetoshi Yoshida, MD; Yasuyuki Sone, MD
Author and Funding Information

Department of Thoracic Surgery, Tokyo Women's Medical Unversity Yachiyo Medical, Chiba, Japan


Chest. 2009;136(4_MeetingAbstracts):13S. doi:10.1378/chest.136.4_MeetingAbstracts.13S-h
Text Size: A A A
Published online


PURPOSE:  The purpose of this retrospective study was to investigate long-term graft patency and outcomes for malignant diseases.

METHODS:  From October 1995 to November 2008, twenty patients underwent combined surgical resection of malignant tumors and the superior vena cava with vascular reconstruction using ringed polytetrafluoroethylene (PTFE) graft at three thoracic surgical centers. Sigmoid-curved cutting of the graft-end at right auricle side was performed for obtaining wide opening of a left graft in bilateral graft patients. Anti-coagulation therapy was routinely performed for at least three months. Graft patency was verified by venography or contrast-enhanced computed tomography at two to four weeks and 3 months after operation. Ten patients were lung cancer, eight were thymic cancer or invasive thymoma (with myasthenia gravis in four patients) and two were germ cell tumors.

RESULTS:  Nine patients received single graft replacement, ten received bilateral, and one received bilateral SVC grafts and one pulmonary artery graft. All grafts were patent at short-term periods, but one of the two grafts experienced occlusion in two bilateral graft patients at long-term period. Postoperative temporary facial edema was identified in three patients who received single graft, but no facial edema was identified in patients with bilateral grafts. One in-hospital death was identified due to bronchial dehiscence in lung cancer. Mean follow-up was 44.7 months. Median survival was 22.1 months and overall survival was 66.4% and 41.5% at one and five years, respectively. Lung cancer was significantly worse long term survival than the other two groups Five year survivals were 16.7% in lung cancer, 62.5% in thymic tumor and 100% in germ cell tumors (p=0.024). Only two out of eight lung cancer patients with nodal involvement survived.

CONCLUSION:  Both single and double reconstructions are feasible and effective treatment for invasive malignant diseases. However, indication of SVC reconstruction for lung cancer should be carefully considered in patients with nodal involvements.

CLINICAL IMPLICATIONS:  SVC reconstruction can be performed with low mortality and graft occlusion for effective treatment of mediastinal malignancies.

DISCLOSURE:  Yasuo Sekine, No Financial Disclosure Information; No Product/Research Disclosure Information

Monday, November 2, 2009

10:30 AM - 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543